TRASTUZUMAB
HER2 Positive Solid Tumor
Radboud University Medical Centermonoclonal_antibodyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the HER2 Positive Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zanidatamab Haihua Yuan | Phase 2 | CCC |
kn046 Peking University | Phase 1 | CC |
ANTI-HER2 BSAB KN026 Peking University | Phase 1 | CC |
Same molecule, other indications
TRASTUZUMAB is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →